コンテンツへスキップ
Merck
  • Association between arterial stiffness and serum L-octanoylcarnitine and lactosylceramide in overweight middle-aged subjects: 3-year follow-up study.

Association between arterial stiffness and serum L-octanoylcarnitine and lactosylceramide in overweight middle-aged subjects: 3-year follow-up study.

PloS one (2015-03-18)
Minjoo Kim, Saem Jung, Sang-Hyun Lee, Jong Ho Lee
要旨

Existing data on the association between being overweight and cardiovascular morbidity and mortality risk in adults are inconsistent. We prospectively and longitudinally investigated the effects of weight on arterial stiffness and plasma metabolites in middle-aged subjects (aged 40-55 years). A group of 59 individuals who remained within the range of overweight during repeated measurements over a 3-year period was compared with a control group of 59 normal weight subjects who were matched for age and gender. Changes in metabolites by UPLC-LTQ-Orbitrap mass spectrometry and changes in brachial-ankle pulse wave velocity (ba-PWV) were examined. At baseline, the overweight group showed higher BMI, waist circumference, triglyceride, free fatty acid (FFA), glucose, insulin, and hs-CRP, and lower HDL-cholesterol than controls. After 3 years, the changes in waist circumference, diastolic and systolic blood pressure (DBP and SBP), triglyceride, FFA, glucose, insulin, hs-CRP, and ba-PWV observed in the overweight group were significantly different from those in the control group after adjusting for baseline levels. Furthermore, the overweight group showed greater increases in L-octanoylcarnitine (q=0.006) and decanoylcarnitine (q=0.007), and higher peak intensities of L-leucine, L-octanoylcarnitine, and decanoylcarnitine. Multiple linear regression analysis showed that the change in ba-PWV was independently and positively associated with changes in L-octanoylcarnitine, lactosylceramide, and SBP, and with baseline BMI. Our results indicate that the duration of overweight is an important aggravating factor for arterial stiffness, especially during middle age. Additionally, an age-related increase in plasma L-octanoylcarnitine, lactosylceramide, SBP, and baseline BMI are independent predictors of increased arterial stiffness in middle-aged individuals.

材料
製品番号
ブランド
製品内容

Supelco
アセトアミノフェン, Pharmaceutical Secondary Standard; Certified Reference Material
現在、価格および在庫状況を閲覧できません。
USP
アセトアミノフェン, United States Pharmacopeia (USP) Reference Standard
現在、価格および在庫状況を閲覧できません。
Sigma-Aldrich
アセトアミノフェン, BioXtra, ≥99.0%
現在、価格および在庫状況を閲覧できません。
Sigma-Aldrich
アセトアミノフェン, meets USP testing specifications, 98.0-102.0%, powder
現在、価格および在庫状況を閲覧できません。
Sigma-Aldrich
アセトアミノフェン, analytical standard
現在、価格および在庫状況を閲覧できません。
パラセタモール, European Pharmacopoeia (EP) Reference Standard
現在、価格および在庫状況を閲覧できません。
Sigma-Aldrich
レセルピン
現在、価格および在庫状況を閲覧できません。
Sigma-Aldrich
レセルピン, crystallized, ≥99.0% (HPLC)
現在、価格および在庫状況を閲覧できません。
Sigma-Aldrich
テルフェナジン
現在、価格および在庫状況を閲覧できません。
Supelco
Acetaminophen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
現在、価格および在庫状況を閲覧できません。
Supelco
スルファジメトキシン, Pharmaceutical Secondary Standard; Certified Reference Material
現在、価格および在庫状況を閲覧できません。
Supelco
レセルピン, analytical standard, for LC-MS
現在、価格および在庫状況を閲覧できません。
Supelco
スルファジメトキシン, VETRANAL®, analytical standard
現在、価格および在庫状況を閲覧できません。
Supelco
スルファジメトキシン, 98.0-102.0%
現在、価格および在庫状況を閲覧できません。
レセルピン, European Pharmacopoeia (EP) Reference Standard
現在、価格および在庫状況を閲覧できません。
テルフェナジン, European Pharmacopoeia (EP) Reference Standard
現在、価格および在庫状況を閲覧できません。
スルファジメトキシン, European Pharmacopoeia (EP) Reference Standard
現在、価格および在庫状況を閲覧できません。